Twin Health secures $50 million in funding led by Temasek, augmenting its AI-driven Whole Body Digital Twin model targeting metabolic diseases like Type 2 diabetes. The investment aims to expand technology deployment across health plans and employers, promising improved outcomes and reduced costs. Similar ventures like Mesh Bio and Unlearn highlight the growing influence of digital twin technology in managing chronic diseases and optimizing clinical trials.
Digital metabolic care startup Twin Health announced it raised $50 million in funding, two years after securing $140 million in Series C funding.
Temasek led the funding with participation from existing investors Sofina, ICONIQ Growth, Helena, and Peak XV.
WHAT IT DOES
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Twin’s product is the Whole Body Digital Twin, an AI-backed model that aims to provide individualized nutrition, sleep and activity guidelines to help people prevent and reverse metabolic diseases such as Type 2 diabetes.
“The funding will help propel our strategy to scale the availability of our transformative technology and the way it’s deployed to even more health plans and employer partners, achieving lower costs, better outcomes and higher satisfaction among their members and employees,” Jahangir Mohammed, founder and CEO of Twin Health, said in a statement.
MARKET SNAPSHOT
A survey of TATA Consultancy Services futurists and their peers conducted earlier this year by TCS, a global IT services, consulting and business services organization, revealed experts believe digital twins will reshape society by 2035, with broad adoption in healthcare within the next six years.
Singaporean startup Mesh Bio is another company working on digital twin technology. It focuses on utilizing digital twins to help manage rising cases of chronic diseases, particularly in Southeast Asia, where 62% of all deaths in the region are due to non-communicable conditions.
Clinical trial tech company Unlearn uses a machine learning model to create digital twins of randomized controlled trial participants, which the company pitches as a way to run smaller clinical trials more quickly since they don’t need to find as many participants for the control group.
Unlearn scored $50 million in Series B funding last year, bringing its total raise to nearly $70 million.
Source: Mobihealth News
